Evidence map›Paper›PMID 20012639›Full record

Trial reportLung2010

Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis.

Robert M Jackson, Marilyn K Glassberg, Carol F Ramos, Pablo A Bejarano, Ghazwan Butrous, Orlando Gómez-Marín

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Lung, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00359736 (Vasodilator Therapy and Exercise Tolerance in IPF Patients), which is not on this map. Cited by 31 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 6 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00359736 phase2completednot on this map

Vasodilator Therapy and Exercise Tolerance in IPF Patients

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2006 to 2009Enrolled29ConditionsAlveolitis, Fibrosing, Fibrosis, Pulmonary, Hypertension, PulmonaryArmssildenafil
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 6 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Phosphodiesterase 5 inhibitors for pulmonary hypertension.The Cochrane database of systematic reviews · 2019
    Pooled it
  5. Pooled it
  6. Guideline
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Robert M JacksonMedicine/Pulmonary, University of Miami, Miami, FL 33101, USA. rjackson2@med.miami.edu
Marilyn K Glassberg
Carol F Ramos
Pablo A Bejarano
Ghazwan Butrous
Orlando Gómez-Marín
University of Miami · USMiami VA Healthcare System · USUniversity of Kent · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia characterized by temporally and spatially heterogeneous fibroblast proliferation and poor prognosis. No therapies have been shown in randomized clinical trials (RCT) to influence survival. Twenty-nine subjects were assigned randomly in a pilot study to a double-blind, placebo-controlled, RCT to test sildenafil in patients with IPF with forced vital capacity 40-90% and diffusing capacity 30-90% of predicted. During the 6-month experimental treatment period, patients underwent 6-min walk tests and estimation of dyspnea using the Borg scale at baseline (0 months), 3 months, and 6 months. Participants had moderate impairment of pulmonary function, and there were no significant differences between placebo (n = 15) and sildenafil (n = 14)-treated groups. Sildenafil did not significantly increase 6-min walk test distance (mean distance +/- SD after 6-month protocol: placebo 355 +/- 82 m, sildenafil 324 +/- 41 m; p = 0.256) nor did it lessen dyspnea after exercise (mean Borg score after 6-month protocol: placebo 3.4 +/- 1.6, sildenafil 4.1 +/- 2.3; p = 0.492). Adverse reactions were few and minor in nature. In this trial, sildenafil did not significantly increase 6-min walk test distance or decrease the Borg dyspnea index in patients with clinically typical IPF. This trial was registered at clinicaltrials.gov as NCT00359736.

Indexed as

AgedAged, 80 and overDouble-Blind MethodDyspneaExercise TestExercise ToleranceFemaleHumansIdiopathic Pulmonary FibrosisMaleMiddle AgedPhosphodiesterase InhibitorsPilot ProjectsPiperazinesPulmonary Diffusing CapacityPurinesPhosphodiesterase InhibitorsPiperazinesPurinesSildenafil CitrateSulfonesVasodilator Agents

Identifiers

PMID20012639
OpenAlexW2029732141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.